Nedostatak povezanosti antihipertenzivnih lijekova s rizikom i ozbiljnošću COVID-19: meta-analiza.
Journal of cardiology
Sažetak istraživanja
Pozadina Povezanost antihipertenzivnih lijekova s rizikom i ozbiljnošću COVID-19 ostaje nepoznata.
Metode i rezultati Sistematski smo pretraživali PubMed, MEDLINE, The Cochrane Library, Cochrane Central Register of Controlled Trials (CENTRAL), ClinicalTrials.gov i medRxiv u potrazi za publikacijama prije 13. jula 2020. Odabrani su (ACEI), blokatori receptora angiotenzina II (ARB), blokatori kalcijumskih kanala (CCB), β-blokatori i diuretici s rizikom i ozbiljnošću COVID-19. Modeli nasumičnih ili fiksnih efekata su korišteni za objedinjavanje omjera šansi (OR) sa 95% intervalom povjerenja (CI) za ishode. Pretraživanje literature dalo je 53 studije koje su zadovoljile naše kriterijume uključivanja, koje su se sastojale od 39 kohortnih studija i 14 studija slučaj-kontrola. Ove studije su uključile ukupno 2.100.587 učesnika. Nismo uočili povezanost između prethodne upotrebe antihipertenzivnih lijekova uključujući ACEI/ARB, CCB, β-blokatore ili diuretike i rizika i težine COVID-19. Dodatno, kada su uključeni samo hipertenzivni pacijenti, težina i mortalitet su bili niži uz prethodnu upotrebu ACEI/ARB-a (ukupni OR od 0,81, 95% CI 0,66-0,99, p
Zaključci Uzeti zajedno, upotreba antihipertenzivnih lijekova nije povezana s rizikom i težinom od COVID-19, s obzirom na to da se COVID-19 ne preporučuje u našoj trenutnoj literaturi. ovih lijekova kod pacijenata oboljelih od COVID-19. Meta-analiza je registrirana na OSF-u (https://osf.io/ynd5g).
Prikaži originalni naslov i sažetak na engleskom
Lack of association of antihypertensive drugs with the risk and severity of COVID-19: A meta-analysis.
Background The association of antihypertensive drugs with the risk and severity of COVID-19 remains unknown.
Methods and results We systematically searched PubMed, MEDLINE, The Cochrane Library, Cochrane Central Register of Controlled Trials (CENTRAL), ClinicalTrials.gov, and medRxiv for publications before July 13, 2020. Cohort studies and case-control studies that contain information on the association of antihypertensive agents including angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), calcium-channel blockers (CCBs), β-blockers, and diuretics with the risk and severity of COVID-19 were selected. The random or fixed-effects models were used to pool the odds ratio (OR) with 95% confidence interval (CI) for the outcomes. The literature search yielded 53 studies that satisfied our inclusion criteria, which comprised 39 cohort studies and 14 case-control studies. These studies included a total of 2,100,587 participants. We observed no association between prior usage of antihypertensive medications including ACEIs/ARBs, CCBs, β-blockers, or diuretics and the risk and severity of COVID-19. Additionally, when only hypertensive patients were included, the severity and mortality were lower with prior usage of ACEIs/ARBs (overall OR of 0.81, 95% CI 0.66-0.99, p
Conclusions Taken together, usage of antihypertensive drugs is not associated with the risk and severity of COVID-19. Based on the current available literature, it is not recommended to abstain from the usage of these drugs in COVID-19 patients. Registration The meta-analysis was registered on OSF (https://osf.io/ynd5g).
Izvorni podaci
- DOI
- 10.1016/j.jjcc.2020.10.015
- PMID
- 33168337
- PMCID
- PMC7605745
- Provjereno
- 2026-07-26
Naslov i sažetak prevedeni su automatski i prijevod može sadržavati netačnosti ili neprecizne stručne izraze. Za sve detalje, citiranje i medicinsko tumačenje pregledajte originalnu englesku verziju članka. Ne donosite zdravstvene odluke samo na osnovu ovog prijevoda.
Pregledaj originalni članak na engleskom